A novel multiplex system for simultaneous detection of 30 fusion genes in leukemia patients.

Many hematologic malignancies carry characteristic chromosomal translocations. Correct identification of fusion genes can ensure an accurate diagnosis and prognosis is made and can assist in making treatment decisions, stratification, and disease monitoring. Current methodologies used to detect fusion genes can be laborious and time-consuming, typically involving karyotyping, followed by fluorescence-in situ hybridization (FISH) and molecular analysis based on reverse transcriptase polymerase chain reaction (RT-PCR).

QuanDx’s novel Leukemia Fusion Gene (Q30) Screening Kit reduces the time, complexity, and costs associated with fusion gene detection for CML, AML, and ALL, yielding rapid results at a fraction of the cost of FISH.

• Multiplexing: Allows simultaneous detection of 30 fusion genes with 140+ breakpoints.

• Compatibility: Compatible with most current real-time qPCR instruments.

• Rapid: Results can be obtained in 2-3 hours.

• Simple: Easy to perform for routine screening.

• Cost Effective: Can be performed for a fraction of the cost of FISH.

Chronic Myeloid Leukemia (CML)

Acute Myeloid Leukemia (AML)

Acute Lymphoblastic Leukemia (ALL)

Leukemia Fusion Genes (Q30) Screening kit is a CE marked product, and for In Vitro Diagnostic Use. Leukemia Fusion Genes (Q30) Screening kit is not FDA cleared.